In vivo evaluation in mice and metabolism in blood of human volunteers of [I-123]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammation

F Dumont*, F De Vos, J Versijpt, HML Jansen, J Korf, RA Dierckx, G Slegers

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    30 Citations (Scopus)

    Abstract

    We report the in vivo evaluation (biodistribution, displacement and metabolization in blood, brain and heart) in mice and the metabolism in blood of human volunteers of iodine-123 labelled 1-(2-iodophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline carboxamide ([I-123]iodo-PK11195), a potential radioligand for visualization of inflammation in humans by single-photon emission tomography. In three series of 18 white mice (NMRI, 20-25 g), the concentration of radioactivity was measured during 48 h, Blood samples were taken, organs and intestines were excised, excretion was collected and all tissues were weighed and counted for radioactivity. The tissue uptake of radioactivity was measured as % of the injected activity/g of tissue. The excretion was expressed as % of the injected activity. Selective tissue uptake was investigated by pretreatment of another three series of 18 mice with cold PK11195 (1 mg/kg body weight). There was an inflow of [I-123]iodo-PK11195 in the brain and among peripheral organs, heart (42.3%), lungs (133.5%) and kidneys (18.4%) had the highest uptake. After pretreatment with cold PK11195, there was a decrease in accumulation in the latter three organs, especially in heart (ca. 55%) and lungs (ca. 80%). Metabolite analysis was performed using high-performance liquid chromatography (HPLC). First, the extraction yield of [I-123]iodo-PK11195 from blood and tissue was assessed, and found to be >90%. From blank blood samples and organs spiked with [I-123]iodo-PK11195 it was concluded that no metabolization took place during the extraction procedure. Analysis of plasma, brain and heart of mice showed that 10 min p.i. [I-123]iodo-PK11195 was the only significant (ca. 95%) radioactive compound in brain and heart where-as in plasma other radioactive products (>60%) appeared. Analysis of plasma samples of the three human volunteers at 7, 20, 37 and 50 min p.i. showed that [I-123]iodo-PK11195 rapidly decomposes into two polar metabolites, which at these time points accounted for, respectively 31%, 62%, 75% and 77% of the total activity.

    Original languageEnglish
    Pages (from-to)194-200
    Number of pages7
    JournalEuropean Journal of Nuclear Medicine
    Volume26
    Issue number3
    Publication statusPublished - Mar-1999

    Keywords

    • in vivo evaluation
    • [I-123]iodo-PK11195
    • mice
    • human volunteers
    • inflammation
    • BENZODIAZEPINE BINDING-SITES
    • AUTORADIOGRAPHIC LOCALIZATION
    • RAT-BRAIN
    • SPECIES-DIFFERENCES
    • AFFINITY BINDING
    • CEREBRAL-CORTEX
    • H-3 PK-11195
    • RECEPTORS
    • HETEROGENEITY
    • LIGANDS

    Cite this